omigapil omigapil omigapil (tch346 or cgp3466) is a drug that was developed by novartis and tested in clinical trials for its ability to help treat parkinson's disease (pd) and amyotrophic lateral sclerosis (als). the development for pd and als have been terminated due to lack of benefit, but santhera pharmaceuticals bought the compound for development for the treatment of congenital muscular dystrophy (cmd). omigapilclinical dataother namestch346, cgp3466batc codenonelegal statuslegal status investigational identifiers iupac name dibenzooxepin-10-ylmethyl-methyl-prop-2-ynylamine cas number181296-84-4pubchem cid6419718chemspider4925351unii5v14hd0n4qcomptox dashboard (epa)dtxsid10171098 chemical and physical dataformulac19h17nomolar mass275.351 g·mol−13d model (jsmol)interactive image smiles c=3c1ccccc1oc2ccccc2c=3cn(c)cc#c inchi inchi=1s/c19h17no/c1-3-12-20(2)14-16-13-15-8-4-6-10-18(15)21-19-11-7-5-9-17(16)19/h1,4-11,13h,12,14h2,2h3key:qlmmogwzcfqapu-uhfffaoysa-n omigapil was first synthesized at ciba-geigy, basel, switzerland. santhera pharmaceuticals has since taken over production of omigapil and preclinical trials for cmd. in may 2008, omigapil was granted orphan designation to commence clinical trials for. pharmacokinetic trials are scheduled to commence enrollment in the second half of 2012 to determine the appropriate pharmacokinetic profile of the drug for children with laminin-α2-deficient congenital muscular dystrophy (mdc1a) and collagen vi related myopathy. santhera pharmaceuticals will use the phase 1 clinical trial to determine if the drug is safe and acts with the same pharmacokinetic profile in children as it does in adults. the impending clinical trial will take place in the united states at the national institute of neurological disorders and stroke/national institute of health(nndcs/ninds) (bethesda, maryland) and in the united kingdom at great ormond street hospital (ucl). mechanism of action omigapil binds to gapdh to block s-nitrosylation, thereby preventing proapoptotic gene expression. omigapil inhibits programmed cell death (apoptosis) through the enzymes glyceraldehyde 3-phosphate dehydrogenase (gapdh) and siah1. the glycolytic housekeeping enzyme gapdh is mediated by neuronal nitric oxide synthase. once activated by nitric oxide, gapdh binds to the ubiquitin ligase siah1, and is transported to the nucleus where it activates the acetyltransferases p300/cbp to enhance acetylation and subsequent transcription. gapdh's targets proapoptotic genes such as p53, p53 upregulated modulator of apoptosis (puma), and p21 as well as other related targets. chemogenetic studies indicate that omigapil inhibits this proapoptotic signaling cascade by preventing gapdh activation through s-nitrosylation, which in turn prevents the binding of siah1 and translocation to the nucleus (see figure). multiple binding cites on gapdh have been suggested. omigapil was originally developed as a structurally similar molecule to selegiline (l-deprenyl), a monoamine oxidase inhibitor (mao) blocking the enzyme mao type b, yet omigapil inhibit neither type of mao. selegiline has proven problematic as a treatment for parkinson's disease because it is metabolized to (meth)amphetamine, which gives rise to adverse effects. due to omigapil's tricyclic nature, the drug cannot be metabolized to amphetamine derivatives. omigapil acts as a neuroprotective agent in cellular and rodent models of parkinson's disease like selegiline, but its neuroprotective action is 100 times more potent than selegiline in both in vivo and in vitro studies. pharmacokinetics omigapil can pass through the blood brain barrier and has oral bioavailability as omigapil mono-maleate salt. studies have demonstrated a bell-shaped dose-response curve for both rodent and primate models. the rhesus monkey dose was optimized between 0.014 and 0.14 mg/kg subcutaneous. in human trials for parkinson's disease, doses of 0.5, 2.5 and 10 mg daily were considered, which resulted in the selection of a dose range of 0.3 to 3 mg daily for a 70 kg individual. unfortunately a biomarker has not been established for omigapil, which means that clinical trials rely on blood plasma levels to measure drug distribution rather than a validated biomarker to specifically measure brain exposure. efficacy in animal models the compound displayed cell-rescuing effects in various models of apoptotic neuronal death, as well as in rodent and non-rodent animal models of neurodegeneration. omigapil rescues in vitro pc12 cells from rotenone toxicity, β-amyloid toxicity, nutrition withdrawal, and lactacystin. additionally, omigapil can prevent nmda and kainate receptor excitotoxicity in rat cortical neurons as well as toxicity from cytosine arabinoside (ara c) in cerebellar granule cells. omigapil also rescues rat oligodendrocytes from ampa receptor excitotoxicity and rat embryonic mesencephalic (midbrain) dopaminergic cells from toxicity by mpp+/mptp. in human neuroblastoma (paju) cells, omigapil can also prevent toxicity from rotenone and gapdh overexpression. omigapil has an active concentration range from about 10−12 m to 10−5 m, with a maximum at about 10−9 m. omigapil prevents neurodegeneration in facial motor neuron axotomy animal models as well as mouse models of progressive motor neuronopathy, mptp-induced nigrostriatal degeneration, and oxidopamine-induced neuronal injury. omigapil also prevents the death of nigrostriatal dopaminergic neurons in monkeys treated with mptp to mimic parkinson's disease symptoms. while omigapil was able to prevent programmed cell death for high-risk cells and prevent deterioration of concomitant motor deficits associated with parkinson's symptoms, omigapil was unable to reverse pre-existing parkinson's symptoms in mptp monkeys. clinical trials parkinson's disease and als based on the preclinical results mentioned above, clinical trials were run for both parkinson's disease and amyotrophic lateral sclerosis, but omigapil proved to be inefficacious for both diseases. it is unclear whether the discrepancy in results between laboratory studies and clinical studies is from improper pathogenesis modeling of the disease in animal models, insufficient doses of the study drug, insensitive clinical endpoints, or abnormal sampling in the patient population. however, the drug was determined to be safe for human use with no notable serious side effects. research congenital muscular dystrophy omigapil can ameliorate congenital muscular dystrophy (cmd) symptoms. this rare yet fatal infant disease has symptoms ranging from severe neonatal hypotonia ("floppy infant syndrome") to peripheral neuropathy, inability to stand or walk, respiratory distress, and eventually premature death in early life. the majority of cmd cases result from a genetic mutation in laminin-α2, a subunit of the laminin-211 protein, which serves as an essential mechanical link between basement membrane and muscle fiber in skeletal and heart muscle. the result is muscle degeneration and demyelination of peripheral nerves. the mouse model of laminin-α2-deficient congenital muscular dystrophy (mdc1a) was found to positively respond to omigapil with inhibition of apoptosis in muscle, reduction of body weight loss and skeletal deformation, increased locomotive activity, and protection from early mortality. furthermore, omigapil was found to be even more effective in improving muscle function and strength when coupled with overexpression of the extracellular matrix molecule mini-agrin in mdc1a mice. omigapil coupled with mini-agrin overexpression works as a dual treatment that enhances mechanical load bearing ability and improves regeneration of muscle in mdc1a mice. given that the technology for mini-agrin administration to skeletal muscle in human subjects is not yet available, omigapil is ready for human clinical trials to help mediate cmd. omigapil has undergone extensive clinical trial scrutiny for parkinson's disease and als, which indicates that the drug is safe to begin clinical trials for congenital muscular dystrophy. depression it has been investigated in vitro in the context of ketamine-like rapid acting antidepressants.